MedPath
FDA Approval

Ibandronate Sodium

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Apotex Corp.
DUNS: 845263701
Effective Date
December 14, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ibandronate(3 mg in 3 mL)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Apotex Inc.

209429182

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Gland Pharma Limited

Apotex Corp.

Apotex Inc.

918601238

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ibandronate Sodium

Product Details

NDC Product Code
60505-6097
Application Number
ANDA204222
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
December 14, 2023
Code: J12U072QL0Class: ACTIMQuantity: 3 mg in 3 mL
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
© Copyright 2025. All Rights Reserved by MedPath